EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway

Sixu Zhou, Baogui Wang, Yingying Wei, Peiru Dai, Yan Chen, Yingyi Xiao, Hongmei Xia, Chunlin Chen, Weihua Yin

Cancer Biomarkers · 2024-05 · 40 (1) · 47-59

DOI: 10.3233/cbm-230090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biomarkers, online erschienen am 01.02.2024. Verfasst von Sixu Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Biological Engineering, Yichun University, Yichun, Jiangxi, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Docetaxel, Phosphatidylinositol 3-Kinases, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Docetaxel is a yew compound antitumor agent with accurate antitumor efficacy, but its application is limited due to the high and serious adverse effects, and finding effective combination therapy options is a viable strategy. Immune checkpoint inhibitors have become hotspots in enhancing anti-tumor immunity by blocking immune checkpoint signaling pathways, but their response rate to monotherapy use is not high and the efficacy is minimal. OBJECTIVE: To explore the anti-tumor effects and mechanisms of the combination of PD-1 inhibitors and Docetaxel through in vivo experiments and develop a feasible combination treatment for the therapy of prostate cancer. METHODS: Tumor-bearing mice were subcutaneously injected with 0.1 ml RM-1 cells. Treatment were taken when the tumor growed up to 3 mm, after which the tumor and spleen were removed to test the antitumor effect with Flow cytometric (FACS) analysis, Immunohistochemistry, Western Blot. RESULTS: In this experiment, we found that PD-1 inhibitors combined with Docetaxel had a synergistic effect on mouse prostate cancer, inhibited the growth of prostate cancer, improved survival and reduced adverse reactions, increased spleen and tumor infiltrative CD4 + and CD8 + T cells, especially in group combination with low-dose Docetaxel, and were related to the PI3K/AKT/NFKB-P65/PD-L1 signaling pathway. CONCLUSION: Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenDocetaxelPhosphatidylinositol 3-KinasesProgrammed Cell Death 1 ReceptorProstatic NeoplasmsProto-Oncogene Proteins c-aktSignal TransductionAnimalsMaleMiceAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDown-RegulationDrug SynergismImmune Checkpoint InhibitorsTranscription Factor RelA

Stichwörter der Autor:innen

PD-1 inhibitorProstate cancercamrelizumabdocetaxelimmune checkpoints

Substanzen

B7-H1 AntigenCd274 protein, mouseDocetaxelImmune Checkpoint InhibitorsPhosphatidylinositol 3-KinasesProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktTranscription Factor RelA

Autor:innen und Institutionen

  • College of Chemistry and Biological Engineering, Yichun University, Yichun, Jiangxi, China.
  • The People's Hospital of Yichun Affiliated to Clinical Medicine School of Yichun University in Jiangxi Province, Yichun, Jiangxi, China.

Zitieren

APA

Zhou, S., Wang, B., Wei, Y., Dai, P., Chen, Y., Xiao, Y., Xia, H., Chen, C., & Yin, W. (2024). PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway. Cancer Biomarkers, 40(1), 47-59. https://doi.org/10.3233/cbm-230090

Vancouver

Zhou S, Wang B, Wei Y, Dai P, Chen Y, Xiao Y, et al. PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway. Cancer Biomarkers. 2024;40(1):47-59. doi:10.3233/cbm-230090

BibTeX
@article{Zhou2024,
  author = {Zhou, Sixu and Wang, Baogui and Wei, Yingying and Dai, Peiru and Chen, Yan and Xiao, Yingyi and Xia, Hongmei and Chen, Chunlin and Yin, Weihua},
  title = {PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway},
  journal = {Cancer Biomarkers},
  year = {2024},
  volume = {40},
  number = {1},
  pages = {47--59},
  doi = {10.3233/cbm-230090}
}
Kostenlos starten →